Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases

Authors: Petra Leidinger, Christina Backes, Michael Blatt, Andreas Keller, Hanno Huwer, Philipp Lepper, Robert Bals, Eckart Meese

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Objectives

In our previous studies we reported a panel of 24 miRNAs that allowed discrimination between blood of lung tumor patients independent of the histological subtype and blood of healthy controls with an accuracy of 95.4% [94.9%-95.9%]. Here, we now separately analyzed the miRNA expression in blood of non-small cell lung cancer (NSCLC), including squamous cell lung cancer and adenocarcinoma, and small cell lung cancer (SCLC) patients.

Patients and methods

In total, we examined the expression levels of 1,205 miRNAs in blood samples from 20 patients from each of the three histological groups and determined differentially expressed miRNAs between histological subtypes and metastatic and non-metastatic lung cancer. We further determined the overlap of miRNAs expressed in each subgroup with the 24-miRNA signature of lung tumor patients.

Results

Based on a raw p-value < 0.05, only 18 blood-borne miRNAs were differentially expressed between patients with adenocarcinoma and with squamous cell lung carcinoma, 11 miRNAs between adenocarcinoma and SCLC, and 2 between squamous cell lung carcinoma and SCLC. Likewise, the comparison based on a fold change of 1.5 did not reveal major differences of the blood-borne miRNA expression pattern between NSCLC and SCLC. In addition, we found a large overlap between the blood-borne miRNAs detected in the three histological subgroups and the previously described 24-miRNA signature that separates lung cancer patients form controls. We identified several miRNAs that allowed differentiating between metastatic and non-metastatic tumors both in blood of patients with adenocarcinoma and in blood of patients with SCLC.

Conclusion

There is a common miRNA expression pattern in blood of lung cancer patients that does not allow a reliable further subtyping into NSCLC or SCLC, or into adenocarcinoma and squamous cell lung cancer. The previously described 24-miRNA signature for lung cancer appears not primarily dependent on histological subtypes. However, metastatic adenocarcinoma and SCLC can be predicted with 75% accuracy.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516CrossRefPubMed
2.
Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger G, Graziano P, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD, Funkhouser WK: Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 world health organization classification and therapeutically relevant subsets. Arch Pathol Lab Med. 2012, 137: 32-40.CrossRefPubMed
3.
Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K, : Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007, 132: 234S-242S. 10.1378/chest.07-1378CrossRefPubMed
4.
5.
Scheff RJ, Schneider BJ: Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. Semin Intervent Radiol. 2013, 30: 191-198. 10.1055/s-0033-1342961PubMedCentralCrossRefPubMed
6.
Rossi G, Pelosi G, Barbareschi M, Graziano P, Cavazza A, Papotti M: Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. Int J Surg Pathol. 2013, 21: 326-336. 10.1177/1066896913489346CrossRefPubMed
7.
Feinstein AR, Gelfman NA, Yesner R: Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis. 1970, 101: 671-684.PubMed
8.
Stang A, Pohlabeln H, Muller KM, Jahn I, Giersiepen K, Jockel KH: Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006, 52: 29-36. 10.1016/j.lungcan.2005.11.012CrossRefPubMed
9.
Dragan AM, Rosca E, Vaida T: Correlations between the results of the histological and cytological examination in the diagnostic of the broncho-pulmonary cancer. Rom J Morphol Embryol. 2005, 46: 311-315.PubMed
10.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-838. 10.1038/nature03702CrossRefPubMed
11.
Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008, 26: 462-469. 10.1038/nbt1392CrossRefPubMed
12.
Fassina A, Cappellesso R, Fassan M: Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest. 2011, 140: 1305-1311. 10.1378/chest.11-0708CrossRefPubMed
13.
Huang W, Hu J, Yang DW, Fan XT, Jin Y, Hou YY, Wang JP, Yuan YF, Tan YS, Zhu XZ, Bai CX, Wu Y, Zhu HG, Lu SH: Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. Am J Respir Crit Care Med. 2012, 186: 1160-1167. 10.1164/rccm.201203-0534OCCrossRefPubMed
14.
Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, Bibbo M, Thurm C, Horowitz L, Huang Y, Feinmesser M, Hou JS, St Cyr B, Burnstein I, Gibori H, Dromi N, Sanden M, Kushnir M, Aharonov R: Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn. 2012, 14: 510-517. 10.1016/j.jmoldx.2012.03.004CrossRefPubMed
15.
Du L, Schageman JJ, Irnov Girard L, Hammond SM, Minna JD, Gazdar AF, Pertsemlidis A: MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res. 2010, 29: 75- 10.1186/1756-9966-29-75PubMedCentralCrossRefPubMed
16.
17.
Russo F, Di Bella S, Nigita G, Macca V, Lagana A, Giugno R, Pulvirenti A, Ferro A: miRandola: extracellular circulating microRNAs database. PLoS One. 2012, 7: e47786- 10.1371/journal.pone.0047786PubMedCentralCrossRefPubMed
18.
Shah MY, Calin GA: The Mix of Two Worlds: Non-Coding RNAs and Hormones. Nucleic Acid Ther. 2012, 23: 2-8.PubMed
19.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA: MicroRNAs in body fluids–the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011, 8: 467-477. 10.1038/nrclinonc.2011.76PubMedCentralCrossRefPubMed
20.
Etheridge A, Lee I, Hood L, Galas D, Wang K: Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011, 717: 85-90. 10.1016/j.mrfmmm.2011.03.004PubMedCentralCrossRefPubMed
21.
Cortez MA, Calin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009, 9: 703-711. 10.1517/14712590902932889CrossRefPubMed
22.
Keller A, Backes C, Leidinger P, Kefer N, Boisguerin V, Barbacioru C, Vogel B, Matzas M, Huwer H, Katus HA, Stahler C, Meder B, Meese E: Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Mol Biosyst. 2011, 7: 3187-3199. 10.1039/c1mb05353aCrossRefPubMed
23.
Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Muller-Quernheim J, Wullich B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos I, Boisguerin V: Toward the blood-borne miRNome of human diseases. Nat Methods. 2011, 8: 841-843. 10.1038/nmeth.1682CrossRefPubMed
24.
Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E: miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009, 9: 353- 10.1186/1471-2407-9-353PubMedCentralCrossRefPubMed
25.
Keller A, Leidinger P, Gislefoss R, Haugen A, Langseth H, Staehler P, Lenhof HP, Meese E: Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 2011, 8: 506-516. 10.4161/rna.8.3.14994CrossRefPubMed
26.
Leidinger P, Keller A, Borries A, Huwer H, Rohling M, Huebers J, Lenhof HP, Meese E: Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer. 2011, 74: 41-47. 10.1016/j.lungcan.2011.02.003CrossRefPubMed
27.
Leidinger P, Keller A, Backes C, Huwer H, Meese E: MicroRNA expression changes after lung cancer resection: a follow-up study. RNA Biol. 2012, 9: 900-910.CrossRefPubMed
28.
Jeong HC, Kim EK, Lee JH, Lee JM, Yoo HN, Kim JK: Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Report. 2011, 4: 383-387.
29.
Patnaik SK, Kannisto E, Mallick R, Yendamuri S: Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One. 2011, 6: e22379- 10.1371/journal.pone.0022379PubMedCentralCrossRefPubMed
30.
Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, McShane LM, Wang E: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010, 16: 430-441. 10.1158/1078-0432.CCR-09-1736PubMedCentralCrossRefPubMed
31.
Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009, 27: 2030-2037. 10.1200/JCO.2008.19.4134CrossRefPubMed
32.
Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E, Fasanella S, Cuorvo LV, Palma PD, Rossi G, Papotti M, Pelosi G, Graziano P, Cavazza A, Denti MA, Barbareschi M: miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol. 2011, 35: 268-275. 10.1097/PAS.0b013e3182068171CrossRefPubMed
33.
Zhang YK, Zhu WY, He JY, Chen DD, Huang YY, Le HB, Liu XG: miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes. J Cancer Res Clin Oncol. 2012, 138: 1641-1650. 10.1007/s00432-012-1240-0CrossRefPubMed
34.
Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH: Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010, 16: 610-619. 10.1158/1078-0432.CCR-09-2638CrossRefPubMed
35.
Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010, 28: 1721-1726. 10.1200/JCO.2009.24.9342CrossRefPubMed
36.
Lin Q, Mao W, Shu Y, Lin F, Liu S, Shen H, Gao W, Li S, Shen D: A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol. 2012, 138: 85-93. 10.1007/s00432-011-1068-zPubMedCentralCrossRefPubMed
37.
Kanitz A, Imig J, Dziunycz PJ, Primorac A, Galgano A, Hofbauer GF, Gerber AP, Detmar M: The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. PLoS One. 2012, 7: e49568- 10.1371/journal.pone.0049568PubMedCentralCrossRefPubMed
38.
Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, Ryken T, Gotway MB, Kim S, Weiss GJ: MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer. 2011, 129: 2621-2631. 10.1002/ijc.25939PubMedCentralCrossRefPubMed
39.
Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, Shyy JY, Liang JT, Chen RH: miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 2012, 72: 3631-3641. 10.1158/0008-5472.CAN-12-0667CrossRefPubMed
40.
Sobin LH, Gospodarowicz MK, Wittekind C: UICC TNM Classification of Malignant Tumours. 2009, New York: Wiley-Blackwell, 7
41.
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001, 125: 279-284. 10.1016/S0166-4328(01)00297-2CrossRefPubMed
42.
Hochberg Y: A sharper bonferroni procedure for multiple tests of significance. Biogeosciences. 1988, 75: 185-193.
43.
Vapnik V: The Nature of Statistical Learning Theory. 2000, New York: Springer, 2CrossRef
44.
Team R: R: A Language and Environment for Statistical Computing. 2008, Vienna: R Foundation for Statistical Computing
Metadata
Title
The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
Authors
Petra Leidinger
Christina Backes
Michael Blatt
Andreas Keller
Hanno Huwer
Philipp Lepper
Robert Bals
Eckart Meese
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-202

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

SOX1 down-regulates β-catenin and reverses malignant phenotype in nasopharyngeal carcinoma

Research

WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells

Research

Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenamatous polyposis coli-mediated colon tumorigenesis

Research

Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer

Research

The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy

Research

Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits